For example, in a lymphoma mouse model, CIN was followed by clonal selection of recurrent CNAs that confer a proliferative advantage (Shoshani et al. 2021; Trakala et al. 2021), including gains of any chromosome (natural or engineered) that carried the c-Myc gene (Trakala et al. 2021). This evidence concerns the gene MYC and lymphoma.